Home > Focus Areas > DLBCL Connect > Post
4yr
Robust anti-tumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells
Source : https://mct.aacrjournals.org/content/early/2021/03/02/1535-7163.MCT-20-0476.abstract
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of patients develop life-threatening toxicities associated with cytokine release syndrome (CRS) which may limit its utilization in low-resource settings.
-
Mark Fesler4yrAlthough current CAR T treatments are often manageable for providers, patients experience frightening and sometimes life threatening toxicities, and this article describes a CAR T with a more favorable AE profile, which is an exciting advance...